Table 2.
eGFR slope during the acute “dip” period (per week) and the readjustment period (per year), by baseline kidney status
| Time Period |
eGFR G1
(eGFR≥90 ml/min per 1.73 m2) |
eGFR G2
(eGFR≥60 and <90 ml/min per 1.73 m2) |
eGFR G3
(eGFR<60 ml/min per 1.73 m2) |
||||||
| Placebo | Ertugliflozin | Difference a | Placebo | Ertugliflozin | Difference a | Placebo | Ertugliflozin | Difference a | |
| Weeks 0–6b | −0.61 | −1.13 | −0.52 | −0.01 | −0.42 | −0.41 | 0.38 | −0.18 | −0.57 |
| (−0.86 to −0.36) | (−1.30 to −0.96) | (−0.82 to −0.22) | (−0.10 to 0.08) | (−0.48 to −0.35) | (−0.52 to −0.30) | (0.26 to 0.50) | (−0.27 to −0.10) | (−0.72 to −0.42) | |
| Weeks 6–52c | −0.14 | 1.97 | 2.11 | −0.27 | 1.49 | 1.76 | 0.25 | 1.49 | 1.25 |
| (−1.58 to 1.31) | (0.95 to 3.00) | (0.33 to 3.89) | (−1.00 to 0.47) | (0.98 to 2.00) | (0.87 to 2.66) | (−0.77 to 1.26) | (0.76 to 2.22) | (−0.01 to 2.50) | |
| Normoalbuminuria | Microalbuminuria | Macroalbuminuria | |||||||
| Weeks 0–6b | −0.09 | −0.51 | −0.42 | −0.03 | −0.55 | −0.52 | −0.05 | −0.68 | −0.63 |
| (−0.22 to 0.04) | (−0.60 to −0.41) | (−0.58 to −0.26) | (−0.20 to 0.13) | (−0.67 to −0.43) | (−0.72 to −0.32) | (−0.3 to 0.21) | (−0.85 to −0.50) | (−0.94 to −0.32) | |
| Weeks 6–52c | 0.03 | 2.18 | 2.16 | −0.05 | 1.13 | 1.18 | −1.53 | −0.36 | 1.16 |
| (−0.71 to 0.77) | (1.66 to 2.71) | (1.25 to 3.06) | (−1.13 to 1.04) | (0.36 to 1.90) | (−0.15 to 2.51) | (−3.59 to 0.54) | (−1.78 to 1.05) | (−1.34 to 3.66) | |
| KDIGO CKD Low Risk | KDIGO CKD Moderate Risk | KDIGO CKD High/Very High Risk | |||||||
| Weeks 0–6b | −0.23 | −0.60 | −0.37 | −0.00 | −0.51 | −0.51 | 0.22 | −0.42 | −0.64 |
| (−0.37 to −0.08) | (−0.70 to −0.50) | (−0.55 to −0.19) | (−0.18 to 0.17) | (−0.63 to −0.39) | (−0.72 to −0.30) | (0.03 to 0.41) | (−0.56 to −0.29) | (−0.88 to −0.41) | |
| Weeks 6–52c | −0.08 | 2.12 | 2.20 | −0.08 | 1.53 | 1.62 | −0.35 | 0.38 | 0.73 |
| (−0.92 to 0.76) | (1.53 to 2.71) | (1.17 to 3.23) | (−1.16 to 0.99) | (0.78 to 2.29) | (0.30 to 2.93) | (−1.59 to 0.89) | (−0.49 to 1.25) | (−0.78 to 2.25) | |
Analysis was performed on the full analysis set population. KDIGO CKD, Kidney Disease Improving Global Outcomes in Chronic Kidney Disease.
a
Difference versus placebo (least squares mean [95% confidence interval]).
b
eGFR slope (least squares mean), ml/min per 1.73 m2 per week (95% confidence interval).
c
eGFR slope (least squares mean), ml/min per 1.73 m2 per year (95% confidence interval).